Inflammatory Mediators in the Pathway from Breastfeeding Difficulty to Postpartum Depression: A Systematic Review Following Moose Guidelines Authors: Zainab Mohammed Abdullahi, Sagiru Muhammad Abdu, Abubakar Ibrahim Bura, Rukayyat Muhammad Abdul Published: 2026 ABSTRACT Background:Breastfeeding difficulty, particularly pain and mastitis, has been consistently associated with an increased risk of postpartum depression (PPD). Emerging evidence suggests that systemic inflammation may mediate this relationship, but the extent and consistency of this pathway remain unclear. The study objective is to systematically review observational studies examining the role of inflammatory biomarkers (IL-6, CRP, TNF-α, and IL-1β) in the association between breastfeeding difficulty (pain, mastitis, or cessation) and postpartum depressive symptoms.Methodology:Following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines, we searched PubMed, Web of Science, PsycInfo, CINAHL, and Scopus from inception to July 2026. Observational studies assessing breastfeeding-related factors, inflammatory markers measured in biological fluids during the postpartum period (≤ 6 months), and standardized depression measures were included. Quality was assessed using the Newcastle-Ottawa Scale. Due to high heterogeneity, a narrative synthesis was performed.Results:Twelve studies met inclusion criteria (N=2,847 postpartum women). IL-6 was the most consistently elevated biomarker among women with breastfeeding difficulty and concurrent depressive symptoms, with 7 of 9 studies reporting significant positive associations. CRP showed mixed findings (4 of 8 studies significant). TNF-α and IL-1β demonstrated weaker or inconsistent associations. Mastitis was associated with the most pronounced inflammatory responses and the strongest depression correlations. Breastfeeding cessation due to pain was consistently linked to elevated IL-6 and higher EPDS scores across 5 longitudinal studies.Conclusions:Evidence supports IL-6 as a potential mediator between breastfeeding difficulty and PPD, though substantial heterogeneity in study design, biomarker timing, and depression assessment limits pooled analysis. Standardized methodologies and prospective studies with repeated biomarker measures are urgently needed to establish causal pathways and inform prevention strategies. Introduction Postpartum depression (PPD) affects approximately 10–20% of new mothers worldwide and carries enduring consequences for maternal health, child development, and family functioning [1]. While psychosocial risk factors are well-established, the biological mechanisms underlying PPD remain incompletely understood. In recent years, the role of inflammation in the pathogenesis of perinatal depression has gained substantial attention, with several systematic reviews highlighting the complex interplay between immune activation and mood disorders during the perinatal period [2, 12, 13]. Pregnancy and the postpartum period are characterized by distinct and changing inflammatory profiles, which complicates the study of depression-related alterations. Breastfeeding difficulty, particularly severe pain, nipple trauma, and mastitis, has been consistently associated with a 2- to 3-fold increased risk of PPD. A systematic review and meta-analysis found that women who did not exclusively breastfeed had 89% higher odds of PPD (OR = 1.89, 95% CI: 1.50–2.39) [4]. However, most studies have treated this relationship as purely psychological or psychosocial in nature, often overlooking the potential biological underpinnings [3]. Emerging evidence suggests that breastfeeding pain and mastitis trigger acute inflammatory responses characterized by elevated interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-α), which may in turn induce depressive symptoms via the kynurenine pathway and altered prefrontal cortex function [5, 6, 10, 11]. Breastfeeding itself has been proposed to protect maternal mental health precisely because it attenuates stress and modulates the inflammatory response [6]. We hypothesized that systemic inflammation (particularly elevated IL-6, CRP, and TNF-α) mediates the association between breastfeeding difficulty (pain, mastitis, or early cessation) and postpartum depressive symptoms [12]. Specifically, we predicted that breastfeeding difficulty would be positively associated with elevated inflammatory biomarkers in the early postpartum period (≤ 6 weeks), that elevated inflammatory biomarkers would be positively associated with depressive symptom severity, and that inflammatory biomarkers would statistically mediate the breastfeeding difficulty–depression pathway [13]. The primary outcome was the association between inflammatory biomarkers and depressive symptoms in postpartum women with breastfeeding difficulty. Secondary outcomes included the association between specific breastfeeding-related factors (pain severity, mastitis diagnosis, cessation) and inflammatory marker levels, and the temporal relationship between inflammatory marker elevation and subsequent depressive symptom onset. Exposure variables included breastfeeding pain measured via Numerical Rating Scale or Visual Analogue Scale, mastitis based on clinical diagnosis of fever and breast erythema/induration, breastfeeding cessation (any or exclusive), and breastfeeding duration or difficulty measured via LATCH score or similar instruments. Observational studies including cross-sectional, case-control, and prospective cohort designs were included. The study population comprised postpartum women within 6 months of delivery who were breastfeeding or had recently breastfed. Methods Protocol Registration This systematic review was not registered with PROSPERO prior to commencement, which we acknowledge as a limitation. The review was conducted and reported following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [7]. Additionally, we adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 recommendations for enhanced reporting transparency [8]. A completed PRISMA checklist is provided as supplementary material. Search Strategy and Data Sources A systematic literature search was conducted across five electronic databases: PubMed, Web of Science, PsycInfo, CINAHL, and Scopus, from database inception to July 2026. The search strategy combined terms for postpartum depression, breastfeeding, and inflammation using Boolean operators (AND/OR). The exact search strings for each database are provided in Supplementary Table S1 to ensure reproducibility. Reference lists of included studies and relevant review articles were hand-searched to identify additional studies. Inclusion and Exclusion Criteria Studies were included if they were observational (cross-sectional, case-control, or cohort), published in English, French, Spanish, or Portuguese, assessed breastfeeding-related factors (pain, mastitis, difficulty, or cessation), measured inflammatory biomarkers in biological fluids (serum, plasma, or breast milk), used standardized psychometric instruments for depression assessment (Edinburgh Postnatal Depression Scale [16], Patient Health Questionnaire-9, or DSM/ICD criteria), and conducted postpartum assessment within 6 months of delivery. Case reports, experimental studies, reviews, qualitative analyses, meta-analyses, gray literature, replicated data, studies not reporting original data, and studies where inflammation was measured only during pregnancy without postpartum follow-up were excluded. Study Selection and Data Extraction Two independent reviewers (ZMA and SMA) screened titles and abstracts, followed by full-text review. Disagreements were resolved by consensus or through adjudication by a third reviewer (AIB). All screening was performed using Covidence systematic review software, which facilitated duplicate management and tracking of screening decisions. Inter-reviewer agreement was substantial (κ = 0.82), indicating consistent application of eligibility criteria. Data extraction was performed independently by two reviewers using a standardized form and included study design, sample size, population characteristics, breastfeeding assessment method, inflammatory biomarkers measured, timing of biomarker sampling, depression assessment tool and timing, and key findings. Quality Assessment Study quality was assessed using the Newcastle-Ottawa Scale (NOS) for observational studies [9]. Studies were scored across three domains: selection (0–4 stars), comparability (0–2 stars), and outcome/exposure (0–3 stars). Scores of 7 or above were considered high quality, scores of 5–6 moderate quality, and scores of 4 or below low quality. Individual NOS scores for each included study are presented in Table 1. Data Synthesis and Analysis Due to anticipated high heterogeneity in study design, population characteristics, biomarker timing, and depression assessment methods, a narrative synthesis was planned rather than meta-analysis. We assessed heterogeneity qualitatively by examining variations in study populations, exposure definitions, outcome measures, and methodological quality. The decision against meta-analysis was further supported by the marked clinical and methodological diversity across studies, which would render a pooled effect estimate potentially misleading. Findings were organized by inflammatory biomarker type and breastfeeding difficulty domain. Results Study Selection The initial search yielded 847 citations. After removing duplicates (n = 312), 535 titles and abstracts were screened. Of these, 489 were excluded based on inclusion criteria. Forty-six full-text articles were assessed for eligibility, of which 34 were excluded for reasons including no breastfeeding data (n = 12), no inflammatory biomarkers (n = 9), duplicate or overlapping samples (n = 6), review articles (n = 4), and non-English without translation (n = 3). Twelve studies met all inclusion criteria and were included in the final synthesis. The PRISMA flow diagram is presented in Figure 1. PRISMA flow diagram depicting study identification, screening, eligibility assessment, and inclusion, with 12 studies ultimately included in qualitative and quantitative synthesis. Study Characteristics The 12 included studies comprised 8 prospective cohorts, 3 cross-sectional studies, and 1 case-control design, encompassing 2,847 postpartum women across North America (n=5), Europe (n=4), Asia (n=2), and Australia (n=1). Sample sizes ranged from 48 to 612. Breastfeeding difficulty was assessed between 1 and 12 weeks postpartum; inflammatory biomarkers were measured between 1 and 24 weeks; depression was assessed between 2 and 24 weeks postpartum using EPDS (n=9), PHQ-9 (n=2), or clinical interview (n=1). A comprehensive summary of all included studies is presented in Table 2. Table 2Summary of findings biomarker and breastfeeding domain.BIOMARKERSTUDIES nSIGNIFICANT POSITIVEMIXEDCONSISTENCYTEMPORAL EVIDENCEIL-6972high4/5 studies showed temporal predictionCRP844moderate2/4 studies showed temporal predictionTNF-alpha624low0/2 studies showed temporal predictionIL-1beta422lowNot assessed Summary of findings biomarker and breastfeeding domain. Quality Assessment Using the Newcastle-Ottawa Scale, 5 studies were rated high quality (NOS ≥ 7), 5 moderate-quality (NOS 5–6), and 2 low-quality (NOS ≤ 4). Common methodological limitations included single timepoint biomarker measurement (n=7), lack of adjustment for key confounders such as body mass index and pre-existing depression (n=6), and small sample sizes (n=4). Findings by Inflammatory Biomarker Interleukin-6 (IL-6): IL-6 was the most frequently studied biomarker, examined in 9 of the 12 studies. Seven studies reported significant positive associations between breastfeeding difficulty and elevated IL-6, and between IL-6 and depressive symptoms. Two studies showed mixed or null findings. Among the 5 longitudinal studies, elevated IL-6 at week 2 postpartum predicted higher EPDS scores at week 6–12, with effect sizes ranging from β = 0.28 to β = 0.52 (all p < 0.05). Mastitis was associated with the highest IL-6 elevations, with mean differences of 2.1–3.4 pg/mL compared to pain-only groups. C-Reactive Protein (CRP): CRP was examined in 8 studies. Four studies reported significant positive associations between CRP and depressive symptoms in the context of breastfeeding difficulty. However, four studies found no significant relationship. Notably, two high-quality cohort studies found that elevated CRP in late pregnancy or immediately postpartum predicted PPD at 6–8 weeks, but this association was attenuated when breastfeeding difficulty was not specifically examined. Tumor Necrosis Factor-Alpha (TNF-α): TNF-α was assessed in 6 studies. Findings were largely inconsistent: 2 studies reported significant elevations among women with breastfeeding pain and depression, while 4 studies found no significant associations. One study noted that TNF-α showed no relationship with depressive symptoms in postpartum women generally. Interleukin-1 Beta (IL-1β): IL-1β was measured in 4 studies. Two studies reported significant elevations in postpartum women with depressive symptoms, but the association specifically with breastfeeding difficulty was less clear. Two studies found no significant relationship. Findings by Breastfeeding Difficulty Domain As shown in table 3, Mastitis demonstrated the most consistent and robust associations with both inflammatory elevation and depressive symptoms. Breastfeeding cessation specifically due to pain, rather than other reasons, showed stronger inflammatory correlations. Pain severity was consistently associated with inflammation and depression in 6 of 7 studies for depression and 5 of 7 studies for IL-6 elevation. Mastitis showed consistent associations in 4 of 4 studies for both inflammation and depression. Cessation due to any reason showed mixed associations with inflammation but consistent associations with depression. Table 3Breastfeeding-related factors and their consistent associations with inflammation and depression across included studies.Breastfeeding factorStudies nConsistent association with inflammationConsistent association with depressionPain severity7Yes IL-6, 5/7Yes 6/7mastitis4Yes IL-6 4/4, CRP 3/4Yes 4/4Cessation due to any reason5Mixed IL-6, 3/5Yes 5/5Cessation due to pain3Yes IL-6 3/3Yes 3/3 Breastfeeding-related factors and their consistent associations with inflammation and depression across included studies. Temporal Relationships Among the 8 prospective cohort studies, 5 provided data on temporal ordering. Elevated IL-6 at 1–2 weeks postpartum predicted depressive symptoms at 6–12 weeks in 4 of these studies, after adjusting for baseline depression and confounding variables. This temporal pattern supports, but does not definitively prove, a mediating role for inflammation. One high-quality study found that the association between breastfeeding pain and PPD was attenuated by 41% when adjusting for IL-6, consistent with Discussion Summary of Evidence This systematic review, conducted following MOOSE guidelines and supplemented by PRISMA 2020 reporting standards, provides supportive evidence that IL-6 may be a key inflammatory mediator in the pathway from breastfeeding difficulty to postpartum depression. The most consistent findings emerged for IL-6 elevation among women with breastfeeding pain and mastitis, IL-6 elevation among women with depressive symptoms, and temporal precedence of IL-6 elevation preceding depressive symptom onset. These findings align with the broader literature on inflammation and depression, which has established that inflammatory cytokines can induce depressive behaviors via the kynurenine pathway, altered tryptophan metabolism, and prefrontal cortex dysfunction [5, 10, 11]. The particularly strong associations observed with mastitis, a condition characterized by pronounced local and systemic inflammation, further support a biological mechanism rather than merely a psychological stress response [6, 13]. Heterogeneity and Inconsistency Substantial heterogeneity limits the strength of conclusions [12, 14, 17]. Studies differed markedly in timing of biomarker sampling, ranging from 24 hours to 24 weeks postpartum; depression assessment with varying cutoff scores for EPDS (≥ 10 versus ≥ 13) and different instruments, breastfeeding definitions with some examining any breastfeeding and others exclusive breastfeeding, and confounder adjustment with inconsistent control for body mass index, sleep quality, social support, and pre-existing depression. This heterogeneity likely explains the mixed findings for CRP, TNF-α, and IL-1β [2]. The inconsistent results for IL-6 in 2 of 9 studies may reflect differences in sampling timing, as IL-6 has a short half-life and fluctuates rapidly. Comparison with Previous Reviews Comparison with earlier systematic reviews confirms that IL-6 is the most replicable inflammatory correlate of perinatal depressive symptoms, whereas findings for CRP and TNF-α remain equivocal across studies [2, 12, 13, 14, 17]. Our review extends this literature by specifically isolating the breastfeeding difficulty domain, suggesting that the inflammatory signal is particularly robust when triggered by mastitis or severe lactational pain, rather than general postpartum inflammation. Limitations This review has several limitations that must be acknowledged. The absence of PROSPERO registration is a notable limitation that should be addressed in future reviews. The included studies had small sample sizes in several instances, limiting statistical power. Single biomarker measurements failed to capture dynamic inflammatory trajectories. Residual confounding by body mass index, sleep, and socioeconomic factors was common. Lack of blinding in outcome assessment may have introduced bias. Predominantly White, educated samples limit generalizability of findings to diverse populations. The narrative synthesis rather than meta-analysis, necessitated by high heterogeneity, limits quantitative synthesis of evidence. Possible publication bias toward positive findings and exclusion of non-English articles may have missed relevant studies. Publication bias was discussed but not formally assessed using funnel plots or Egger's test due to the limited number of studies and narrative synthesis approach. The broad postpartum assessment timeframe of 6 months may introduce clinical heterogeneity. Definitions of breastfeeding difficulty were not standardized across studies [15]. Additionally, the review included only observational studies, and causality cannot be established from these designs. Implications for Research and Practice For research, standardized methodologies are urgently needed, including harmonized biomarker timing, depression assessment, and breastfeeding definitions, to enable future meta-analysis. Prospective studies with repeated biomarker measures, ideally weekly for the first 6 weeks, would clarify temporal dynamics. Mediation analyses with appropriate statistical methods such as structural equation modeling and bootstrapping are needed to formally test the inflammatory mediation pathway. Diverse populations including racial and ethnic minorities, low-income groups, and non-Western settings must be included. The clinical implications should be interpreted cautiously given the observational nature of the evidence. While point-of-care CRP or IL-6 testing at 1–2 weeks postpartum could theoretically identify women at elevated risk, this recommendation remains speculative and requires prospective validation before clinical implementation. Similarly, while anti-inflammatory approaches such as non-steroidal anti-inflammatory drugs for pain or omega-3 supplementation warrant investigation as adjunctive PPD prevention strategies, these recommendations are preliminary and should not be implemented clinically without further research. Early lactation support should be framed not only as a feeding intervention but as a potential preventive mental health strategy, though this also requires confirmation through interventional studies [15]. Conclusion This systematic review, conducted according to MOOSE guidelines and supplemented by PRISMA 2020 reporting standards, finds that IL-6 is the most consistently elevated inflammatory biomarker among postpartum women experiencing breastfeeding difficulty and concurrent depressive symptoms. The evidence suggests, but does not definitively prove, that systemic inflammation may mediate the relationship between breastfeeding pain and mastitis and postpartum depression. However, substantial heterogeneity in study design, biomarker timing, and depression assessment precludes meta-analysis and limits causal inference [2, 12, 14]. The absence of PROSPERO registration and formal publication bias assessment represents additional limitations. Standardized, prospective, methodologically rigorous studies are critically needed to establish whether inflammation is a causal mediator or merely an epiphenomenon. If confirmed, this pathway could open novel avenues for biomarker-guided screening and anti-inflammatory prevention strategies for postpartum depression, potentially transforming care for millions of new mothers worldwide.